Where are we with RSV prophylaxis? - Wikidata - awgldk - TriplyDB

Where are we with RSV prophylaxis?

Where are we with RSV prophylaxis?

http://www.wikidata.org/entity/Q38385728

about

Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.

P2860

Q30245434-0C3D69D3-1A82-4960-BBC5-53792526CD84

P2860

Where are we with RSV prophylaxis?

http://www.wikidata.org/entity/Q38385728

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Where are we with RSV prophylaxis?

@en

type

label

Where are we with RSV prophylaxis?

@en

prefLabel

Where are we with RSV prophylaxis?

@en

P1433

Q38385728-2E176B8A-02DE-4E3A-AC8D-D5AF6448EE23

P1476

Q38385728-3E0FEEC0-E2FC-4DCB-915D-6131D84FDFCC

P2093

Q38385728-62CAB0E0-04DF-40A9-9800-005DF150EB13

Q38385728-75BD73E3-27C2-41B3-831D-44543704C68E

P2860

Q38385728-27B9175D-36A9-4F22-BCA6-D200BB28EA35

Q38385728-29DD175E-6A00-44E9-A9D8-FA38E87A854D

Q38385728-3E2C951B-5F42-43C0-988C-53CA7FC8E564

Q38385728-B964E7B2-2CE1-4CBE-BFBE-54DF74C081C9

Q38385728-CB698576-C800-45BE-83BB-AD44D35BCA4A

Q38385728-D15C36F0-EBFE-4248-ACD1-A09F2B872800

Q38385728-E15FD134-C7F1-4F46-8C72-2F8131C029A6

P304

Q38385728-4F29C3ED-666D-460D-B570-9DD1682E850D

P31

Q38385728-F3C8679E-F7C8-4AD9-80CB-EDAE7510A732

P356

Q38385728-C968F308-1D88-4229-BE70-99997EE8B9F9

P433

Q38385728-21D68509-10B1-4E98-96DB-26D21DBF743B

P478

Q38385728-B815870C-96E6-446C-9B89-59D1ECD38131

P577

Q38385728-EA5F7537-6CB3-4454-9F2B-CD8B5B9C54A2

P698

Q38385728-73A4682A-A48A-4AD3-8128-20073A5B45B7

P356

ARCHDISCHILD-2015-308780

P1433

Archives of Disease in Childhood. Education and Practice Edition

P1476

Where are we with RSV prophylaxis?

@en

P2093

Ceri Townsend

http://www.w3.org/2001/XMLSchema#string

Neil A Caldwell

http://www.w3.org/2001/XMLSchema#string

P2860

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area

Strategies for reducing the risk of respiratory syncytial virus infection in infants and young children: a Canadian nurses' perspective.

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.

Substantial variability in community respiratory syncytial virus season timing.

Possible transmission by fomites of respiratory syncytial virus.

P304

38-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARCHDISCHILD-2015-308780

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26510447

http://www.w3.org/2001/XMLSchema#string